Sustained Intensive Treatment and Long-term Effects on HbA


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
01 2021
Historique:
received: 16 06 2020
accepted: 01 10 2020
pubmed: 18 11 2020
medline: 19 8 2021
entrez: 17 11 2020
Statut: ppublish

Résumé

Continuous glucose monitoring (CGM) reduces HbA The GOLD trial was a randomized crossover trial performed over 16 months of CGM treatment in people with T1D treated with MDI. People completing the trial ( The primary end point of the change in HbA The SILVER study supports beneficial long-term effects from CGM on HbA

Identifiants

pubmed: 33199470
pii: dc20-1468
doi: 10.2337/dc20-1468
doi:

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin A 0
Hypoglycemic Agents 0
Insulin 0
Silver 3M4G523W1G

Banques de données

figshare
['10.2337/figshare.13042586']
ClinicalTrials.gov
['NCT02465411']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

141-149

Informations de copyright

© 2020 by the American Diabetes Association.

Auteurs

Marcus Lind (M)

Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden marcus.lind@gu.se.
Department of Medicine, NU-Hospital Group, Uddevalla, Sweden.

Arndís F Ólafsdóttir (AF)

Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Medicine, NU-Hospital Group, Uddevalla, Sweden.

Irl B Hirsch (IB)

University of Washington School of Medicine, Seattle, WA.

Jan Bolinder (J)

Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.

Sofia Dahlqvist (S)

Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

Aldina Pivodic (A)

Statistiska Konsultgruppen, Gothenburg, Sweden.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Jarl Hellman (J)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Magnus Wijkman (M)

Department of Internal Medicine and Department of Health, Medicine and Caring Sciences, Linköping University, Norrköping, Sweden.

Erik Schwarcz (E)

Department of Internal Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Henrik Albrektsson (H)

Statistiska Konsultgruppen, Gothenburg, Sweden.

Tim Heise (T)

Profil, Neuss, Germany.

William Polonsky (W)

Department of Medicine, University of California, San Diego, La Jolla, CA.
Behavioral Diabetes Institute, San Diego, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH